SIRPA and hematologic disorder: Clinical trials have confirmed that the potency and efficacy of CD47/SIRPα-based therapy, utilizing CD47-blocking monoclonal antibodies (Abs) or SIRPα-fragment crystallizable (Fc) fusion proteins, is a potent and efficacious approach for treating both solid tumors and hematologic malignancies.